Table 1 Patient demographics and clinical characteristics of all cohorts.

Group

(Sample #)

HC

(n = 72)

PD

(n = 53)

HC

(n = 43)

PD

(n = 28)

HC

(n = 60)

PD

(n = 45)

Gender (m/f)

49/23

40/13

27/16

19/9

44/16

27/18

Age

(mean ± SD, range)

68 ± 9

(45–83)

67 ± 9

(43–84)

58 ± 10

(36–81)

64 ± 6

(41–72)

56.6 ± 10.4

(35–81)

63.2 ± 8.8

(41–75)

Disease Duration (mean ± SD, range)

—

5.5 ± 4.5

(0–20)

—

4.3 ± 3.3

(0–11)

—

3.8 ± 2.4

(0–9)

HY score^a

(mean ± SD, range)

—

2.2 ± 0.5

(1–4)*

—

2.1 ± 0.6

(1–4)

—

2.2 ± 0.4

(2–3)

MMSE^b

(mean ± SD, range)

29.1 ± 1.2

(26–30)

27.4 ± 4.0

(14–30)

27.8 ± 1.4^c

(25–30)

28.0 ± 2.1^c

(23–30)

28.7 ± 1.3

(25–30)

29.0 ± 1.2

(26–30)

UPDRS total^d

(mean ± SD, range)

—

37.6 ± 14.8

(15–73)**

—

41.2 ± 16.5

(19–98)

—

40.5 ± 14.0

(15–73)***

# of Individual Patients

72

53

43

28

22

18

% l-dopa or agonist

—

91%

—

96%

—

94%

Source^e

HBS = 53; PM = 19

HBS = 35; PM = 18

HBS = 26; CU = 17

HBS = 8;

CU = 20

HBS = 60

HBS = 45